The first training course on the prevention and treatment of VTE was successfully held in Dongguan on Sept 24. Sponsored by Dongguan People’s Hospital and named by Kossel Medtech, an integrated enterprise with R&D capabilities in PTCA balloon catheter and PTA balloon catheter. Many prominent clinical experts and hospital administrators attended the conference to share their experiences in the prevention and treatment of VTE.
In the prevention and treatment of VTE, vena cava filter implantation has become an important treatment for the prevention of pulmonary embolism, mentioned the manager of the marketing department of Kossel Medtech..Octoparms® vena cava filter independently developed by Kossel Medtech has been successfully industrialized and has a certain market share in China. She hopes to have the opportunity to combine medical and engineering expertise with other experts to better promote academic research in the field of vascular interventions.
Dongguan city people’s hospital of intervention and vascular surgery XiaoYiMing says professor retrievable inferior vena cava filter is an effective method for prevention and treatment of PE, but need to grasp indications, can recycle recovery as far as possible, it is very important to understand the performance of the filter, imaging measurement don’t bother, accurate as far as possible, in strict accordance with the guidelines for standardized operation, postoperative follow-up and patient management is very important. Recovery times should not be compared and the filter should be removed as soon as possible after treatment.
Deep vein thrombosis often occurs in the lower extremities and is characterized by sudden swelling of the lower extremities, increased skin temperature, pain and inability to walk. If not treated promptly, thrombosis can lead to pulmonary embolism. Ivc filter implantation can be used for the treatment of deep vein thrombosis and also for the prevention of deep vein thrombosis and pulmonary embolism in high-risk groups..Deep vein thrombosis (DVT) and pulmonary embolism (PE) have always been a threat to human health and life. Inferior vena cava filter implantation is effective in reducing the incidence of pulmonary embolism and has been widely used in patients with venous thromboembolism.
The Regional Sales Manager of Kossel Medtech gave a thorough presentation on Kossel Medtech’s in-house Octoparms® vena cava filter. This type of filter has its own invention patent and is the first domestic umbrella long-term recyclable vena cava filter;; It can be inserted through the neck, through the femur, and through the neck recovery. It is characterized by high stability, long payback period, and easy removal. In May 2020, it entered the National Food and Drug Administration (NMPA) innovative medical devices special approval “green channel”, and in August 2021, it was approved by the National Food and Drug Administration (NMPA) to be listed. He noted that Kossel Medtech will uphold ingenuity and dedication to research and development of innovative products to help China’s medical industry thrive.
In this training course, state-of-the-art academic concepts, critical thinking and innovative academic spirit, standardized norms and thinking, refined conception and accurate techniques in the prevention and control of VTE will be passed on to more elite colleagues in vascular surgery. Kossel Medtech will jointly promote the construction and development of the discipline of vascular surgery and fully promote the cause of VTE prevention and control.
